Cell Therapy Market by Cell Type, Therapy Type, Application, End-User

List of Tables

[192 Pages Report] The Cell Therapy Market size was estimated at USD 8.66 billion in 2023 and expected to reach USD 9.60 billion in 2024, at a CAGR 10.93% to reach USD 17.91 billion by 2030.

The cell therapy market encompasses the research, development, manufacturing, and commercialization of products and techniques aimed at treating, mitigating, or preventing diseases by administering living cells. The escalating demand for regenerative medicine and advancements in cellular therapeutics primarily drives the growth of the cell therapy market. The rising investment in research and development and collaborative efforts between pharmaceutical companies and research institutions have accelerated the pipeline for cell therapy products. Furthermore, supportive regulatory frameworks and the designation of fast-track approvals for groundbreaking therapies have been crucial growth stimulants for the market. However, the cell therapy market faces several limitations, such as the high cost of therapies, intricate manufacturing processes, and stringent regulatory requirements, which may slow down market entry. Issues related to the preservation, transport, and shelf-life of cell therapies also present substantial challenges in the market growth. Moreover, breakthroughs in gene editing technologies such as CRISPR/Cas9 have opened new avenues for targeted cell therapies, which could offer precision medicine solutions for previously untreatable conditions. The increasing adoption of 3D bioprinting and artificial intelligence for optimizing cell therapy production holds significant promise for future market expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 8.66 billion
Estimated Year [2024]	USD 9.60 billion
Forecast Year [2030]	USD 17.91 billion
CAGR (%)	10.93%

Cell Type: Advancements in stem cells for therapeutic applications

Differentiated cells are specialized cells that have matured to perform a specific function in the body. Differentiated cells are used in cell therapy due to their high specialization and efficacy in replacing lost or damaged cells of the same type. The significant advantage of differentiated cells lies in their lower risk of tumor formation than stem cells, making them highly preferable for direct therapeutic applications. Stem cells are undifferentiated cells that can evolve into various types of cells and hold enormous potential for regenerative medicine. Stem cells are particularly used for their unique capabilities to self-renew and differentiate into multiple cell types, making them suitable for a broad range of therapeutic applications.

Therapy Type: Increasing adoption of autologous cell therapies for personalized medicines

Allogeneic cell therapies involve transplanting cells from a healthy, genetically different donor into a patient. Allogeneic cell therapies are not specific to the individual patient and can be manufactured in larger batches, often called "off-the-shelf" products. Allogeneic therapies are preferred when patients require immediate treatment and do not have time to harvest and expand their cells. Autologous cell therapies are derived from the patient's own cells, which are collected, developed, modified if needed, and then reintroduced into the patient's body. Autologous cell therapies are uniquely tailored to each patient, making them an ideal form of personalized medicine. Autologous therapies are often the choice for treatments requiring the patient's own cellular material to eliminate chances of immunological rejection.

Application: Advancements in dermatological applications of cell therapies

Cell therapies for autoimmune diseases aim to provide innovative treatments that can modulate or reset the immune system. Autoimmune patients require treatments that can provide long-term relief without the adverse effects associated with long-term immunosuppression. Regenerative cell therapies offer potential cures for autoimmune disease conditions that previously had limited treatment options. The application of cell therapies in dermatology primarily addresses skin regeneration for burn victims, reconstruction following surgery, chronic wounds, and cosmetic skin rejuvenation. For patients suffering from burns or chronic wounds, cell therapies accelerate healing and reduce scar tissue formation. Dermatological & cosmetic applications leverage regenerative capabilities to improve skin appearance and health. Cell therapies in the musculoskeletal domain target conditions such as osteoarthritis, bone fractures, and cartilage repair. Cell therapies focus on harnessing the regenerative potential of stem cells for repair and regenerate damaged tissues. Cell therapy plays a critical role in oncology, with CAR-T cell therapy being a revolutionary approach in cancer treatment, including leukemia, lymphoma, and multiple myeloma.

End-User: Diverse applications of cell therapies in hospitals and clinics for disease management

Biotechnology and pharmaceutical companies are primary end-users in the cell therapy market as developers and providers of therapeutic solutions. Biotechnology companies focus on the discovery, development, and commercialization of cell therapies for a variety of diseases, including cancer, autoimmune disorders, and genetic diseases. Their need-based preference is driven by advancements in cellular science, the demand for innovative treatments, and the potential for significant financial returns from successful therapies. Hospitals and clinics represent another crucial segment in the cell therapy market, as they are essential for administering cell therapies to patients. The preference for specific cell therapies often depends on efficacy, safety profiles, cost-effectiveness, and reimbursement policies. Hospitals affiliated with large healthcare networks or academic institutions may have a greater capacity for adopting novel cell therapies due to in-house expertise and infrastructure. Research institutes serve a fundamental role in the cell therapy end-user landscape by conducting basic and translational research to advance the field. Research institutes seek to understand disease mechanisms and develop innovative therapies through grant-funded or internally-financed projects.

Regional Insights

In the Americas region, the United States and Canada lead in cell therapy advancements, driven by significant research, heavy investment, and active participation from biotechnological and pharmaceutical giants. The regulatory framework in the region allows for an expedited review of novel cell therapies, hastening up the process of bringing new treatments to market. The European countries exhibit a cooperative approach towards cell therapy research, with various cross-country partnerships and funding programs supported by public and private sectors. Customer behavior in the EU is influenced by a strong predisposition towards state-funded healthcare systems, which affects access to and affordability of cell therapies. The Middle East and Africa (MEA) present a diverse picture, with countries such as Israel, UAE, and Saudi Arabia taking strides in cell therapy, while many African nations are still developing capabilities in this area. In the APAC region, the governments in China, India, and Japan have initiated several investments and reforms to fast-track local cell therapy research and commercialization. The rising prevalence of cancers and genetic diseases in the region is significantly increasing the need for cell-based therapies for disease management.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., BioNTech SE, Bone Therapeutics SA, Bristol-Myers Squibb Company, Castle Creek Biosciences, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc., Lonza Group Ltd., Medipost Co., Ltd., Mesoblast Ltd., Novartis AG, NuVasive, Inc., Pfizer Inc., Sartorius AG, Smith & Nephew PLC, Stemedica Cell Technologies, Inc., Stempeutics Research Pvt. Ltd., Takeda Pharmaceutical Company Limited, TegoScience, Thermo Fisher Scientific, Inc., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Cell Type
- Differentiated Cell
- Stem Cell

Therapy Type
- Allogenic Therapies
- Autologous Therapies

Application
- Autoimmune Diseases
- Dermatology
- Musculoskeletal Therapies
- Oncology

End-User
- Biotechnology and Pharmaceutical Companies
- Hospitals and Clinics
- Research Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Cell Therapy Market?

4. What is the market share of the leading vendors in the Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Cell Therapy Market?

Product Code: MRR-433AB1DC28D4

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
  - 5.1.1.2. Improvements in Cell Therapy Supply Chain
- 5.1.2. Restraints
  - 5.1.2.1. Side Effects Related to the Stem Cell Transplant
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
  - 5.1.3.2. Increasing Use of Stem Cells for the Treatment of Neurological disorders
- 5.1.4. Challenges
  - 5.1.4.1. Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues
5.2. Market Segmentation Analysis
- 5.2.1. Cell Type: Advancements in stem cells for therapeutic applications
- 5.2.2. Therapy Type: Increasing adoption of autologous cell therapies for personalized medicines
- 5.2.3. Application: Advancements in dermatological applications of cell therapies
- 5.2.4. End-User: Diverse applications of cell therapies in hospitals and clinics for disease management
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Cell Therapy Market, by Cell Type

6.1. Introduction
6.2. Differentiated Cell
6.3. Stem Cell

7. Cell Therapy Market, by Therapy Type

7.1. Introduction
7.2. Allogenic Therapies
7.3. Autologous Therapies

8. Cell Therapy Market, by Application

8.1. Introduction
8.2. Autoimmune Diseases
8.3. Dermatology
8.4. Musculoskeletal Therapies
8.5. Oncology

9. Cell Therapy Market, by End-User

9.1. Introduction
9.2. Biotechnology and Pharmaceutical Companies
9.3. Hospitals and Clinics
9.4. Research Institutes

10. Americas Cell Therapy Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cell Therapy Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cell Therapy Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Pluri Launches New Cell Therapy CDMO Division
- 13.3.2. Max Healthcare Launches CAR-T Cell Therapy to Improve Cancer Care in Delhi-NCR
- 13.3.3. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio